SCHEMBL3286926

SCHEMBL3286926

Cc1ccc(C(CC(N)=O)N2CC3CNCC3C2)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 3/20 0.41
SLC6A2 P23975 9/20 0.37
SLC6A4 P31645 8/20 0.37
TACR1 P25103 1/20 0.36
SLC6A3 Q01959 7/20 0.35
S1PR1 P21453 1/20 0.35
CHRNB2 P17787 3/20 0.34
CHRNB4 P30926 3/20 0.34
CHRNA3 P32297 3/20 0.34
CHRNA7 P36544 3/20 0.34
CHRNA4 P43681 3/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3281863 0.83 HCRTR1 (0.48) TNF
SCHEMBL4691021 0.82 TNF (0.38) TNFSLC6A2SLC6A4TACR1SLC6A3
SCHEMBL4695192 0.81 TNF (0.38) TNFSLC6A2SLC6A4TACR1SLC6A3
SCHEMBL4690403 0.81 HCRTR1 (0.39) TNFTACR1S1PR1PDE4B
SCHEMBL4694334 0.81 HCRTR1 (0.43) TNFTACR1
SCHEMBL4692448 0.81 EPHX2 (0.46) KDM4E
SCHEMBL4693098 0.81 TNF (0.38) TNFS1PR1PDE4APDE4BPDE4C
SCHEMBL4695972 0.80 CHRNB2 (0.40) TNFCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL4692886 0.80 ALDH1A1 (0.42) TNF
SCHEMBL4695935 0.80 HCRTR2 (0.47) TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714018-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2010-05-11 US disclosed
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP disclosed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 US disclosed
US-20060014767-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014767-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 TNF 311/4885SLC6A2 2776/4885SLC6A4 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.